SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...


RoboCT, a technology-driven enterprise, takes technology innovation as its core driving force and is committed to exoskeleton robot technology, robot core components and intelligent control technology. They focus on the fields of rehabilitation and elderly care through the combination of human-computer interaction technology, artificial intelligence technology, data analysis and cloud computing, providing intelligent products and solutions for medical and healthcare institutions and individual users.
Website